In our previous issue, we carried out a story titled, “How MNCs are exploiting Haemophilia” in which a deep-rooted nexus of foreign pharma companies with the doctors, procurement bodies and certain patient group organizations in India, was exposed. This nexus kept the price of certain medicine at artificially higher levels. In this issue, we bring to our readers how, the same foreign pharma companies, are also violating the price caps fixed by the Indian government for this essential medicine and charging 317 per cent more than price fixed by National Pharmaceutical Pricing Authority (NPPA) for a 250 IU Factor-VIII anti-hemophilic medicine.
